GLP-1的故事里，中国玩家终于又交上了新答卷。 最近，银诺医药自研的长效GLP-1药物依苏帕格鲁肽α注射液（商品名“怡诺轻”）获国家药监局批准上市，用于治疗成人2型糖尿病。2月11日，“怡诺轻”在线下公立医院开出了全国首张处方。 据悉，依苏帕格鲁肽α已经在京东健康、阿里健康两大电商平台开启预约，并将于2月18日正式首发，线上开售。 2021年左右，诺和诺德的司美格鲁肽“点燃”全球GLP-1市场之 ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A once weekly injection of semaglutide, the main ingredient in Ozempic and Wegovy, may help problem drinkers kick their cravings.In a new study, the drug, known ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...

Related Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users Massive study looks at benefits, risks of GLP-1 weight-loss drugs FDA says shortage of GLP-1 drug tirzepatide is ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.